Tesamorelin
01 Summary
A GHRH analogue that prompts your own pituitary to release growth hormone. It has unusually strong evidence for one thing in particular: reducing deep abdominal (visceral) fat.
02 How it works
Tesamorelin copies the hormone that tells the pituitary to release growth hormone, so it raises GH in the body’s natural pulsing pattern rather than replacing it. Higher GH and IGF-1 shift the body toward burning fat — especially the visceral fat packed around the organs.
03 Common uses
04 Run profile
A short, gentle first week, then a steady daily amount. Usually taken in the evening, in twelve-week blocks with a four-week break.
The profile shows the shape. Ask for the numbers for your vial, your goal and your timeline.
05 Pairs well with
06 What to watch for
Joint aches, water retention or swelling, tingling, and injection-site reactions are the most reported. It can raise blood sugar, so diabetes needs monitoring. Not for pregnancy, or anyone with active cancer or pituitary problems.
07 Evidence & status
Approved (as Egrifta®)Strong: multiple randomised trials show significant visceral-fat reduction, which led to its approval.
FDA-approved as Egrifta® to reduce excess abdominal fat in HIV-associated lipodystrophy. Other uses are off-label.
08 FAQ
Is it the same as taking growth hormone?
No — it prompts your own pituitary to release GH in natural pulses, rather than adding GH directly.
Why evenings?
Natural GH release peaks during sleep, so evening dosing works with that rhythm.
How long until results?
Visceral-fat changes in trials were measured over months, not weeks.
Educational information only — not medical advice. The Daily Stack does not sell or supply any products. Talk to a licensed healthcare professional about your own health decisions.